Provided by Tiger Trade Technology Pte. Ltd.

HBM HOLDINGS-B

13.860
+0.3202.36%
Volume:9.94M
Turnover:138.86M
Market Cap:12.04B
PE:126
High:14.360
Open:13.580
Low:13.580
Close:13.540
52wk High:17.070
52wk Low:9.460
Shares:869.00M
HK Float Shares:869.00M
Volume Ratio:0.95
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.110
ROE:23.97%
ROA:10.88%
PB:3.67
PE(LYR):126.00
PS:8.57

Loading ...

Hbm Holdings - IF Such Enhanced Damages Are Granted in Full, Award Could Increase to up to Approximately US$60.6 Mln

THOMSON REUTERS
·
Jun 15

Hbm Holdings - Harbour Antibodies Is Entitled to Damages of US$20.2 Mln Being Full Amount Requested at Trial

THOMSON REUTERS
·
Jun 15

HBM Holdings (SEHK:2142) Stock Valuation After New IND Milestone For Cancer Antibody HBM7004

Simply Wall St.
·
Jun 13

Amgen owes $20.2 million in antibody patent lawsuit, US jury says

Reuters
·
Jun 13

Harbour BioMed appoints Sana Biotechnology CSO Dhavalkumar Patel as scientific advisor

Reuters
·
Jun 12

Press Release: Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

Dow Jones
·
Jun 12

Harbour BioMed appoints Luisa Salter-Cid as scientific advisor

Reuters
·
Jun 11

BUZZ-China's HBM climbs on regulator's nod on application of new cancer drug

Reuters
·
Jun 10

Hong Kong Stocks Show Movement: Super-Long-Acting Anti-TSLP Antibody Phase II Trial Completes First Dosing; HBM Holdings-B and SKB BIO Both Surge Over 5% During Session

Stock News
·
Jun 10

HBM Holdings Partner Doses First Patient in SKB378 COPD Study

MT Newswires Live
·
Jun 10

HBM Holdings Secures NMPA IND Acceptance for Bispecific Antibody HBM7004 in Advanced Solid Tumors

Bulletin Express
·
Jun 10

HBM HOLDINGS-B Receives NMPA Acceptance for Investigational New Drug Application of HBM7004

Stock News
·
Jun 10

HBM Holdings says China NMPA accepts IND for HBM7004 in advanced solid tumors

Reuters
·
Jun 10

Hbm - Nmpa Accepts Ind Application for Hbm7004 for Advanced Solid Tumors

THOMSON REUTERS
·
Jun 10

HBM advances respiratory pipeline: first patients dosed in global Phase II SIRIUS COPD study for ultra long-acting antibody HBM9378/WIN378

Bulletin Express
·
Jun 09

HBM HOLDINGS-B Announces First Patient Dosed in Phase II COPD Trial for Its Long-Acting TSLP Antibody

Stock News
·
Jun 09

Kelun-Biotech says partner Windward Bio doses first patients in Phase 2 COPD trial of SKB378/WIN378

Reuters
·
Jun 09

HBM Holdings says first patients dosed in Phase II SIRIUS COPD trial of anti-TSLP antibody HBM9378/WIN378

Reuters
·
Jun 09

HBM Holdings-B Completes HK$74.90 Million Share Buyback in May; Outstanding Share Count Drops by 5.24 Million

Bulletin Express
·
Jun 04

HBM HOLDINGS-B Shares Surge Over 5% on Positive Preclinical Data for AI-Derived Drug Candidate

Stock News
·
Jun 04